본문 바로가기
KERD
논문KCI 등재

Current Challenges for the Early Detection of Alzheimer’s Disease: Brain Imaging and CSF Studies

Yi Li|Rachel Mistur|Lisa Mosconi|Susan De Santi|Marla Guzman|Wai Tsui|Mony J. de Leon
대한신경과학회 (Korean Neurological Association)|2009.12|Journal of Clinical Neurology|제5권 제4호|pp. 153-166

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Alzheimer diseasePETCSF markers

초록

The development of prevention therapies for Alzheimer’s disease (AD) would greatly benefit from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical stage of the disease. Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of AD. In vivo brain 2-[ 18 F]fluoro-2-Deoxy-D-glucose-positron emission tomography (FDG-PET) imaging demonstrates consistent and progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before the onset of symptoms. This review will give an overview of FDG-PET results in individuals at risk for developing dementia, including: presymptomatic individuals carrying mutations responsible for early-onset familial AD; patients with Mild Cognitive Impairment (MCI), often a prodrome to late-onset sporadic AD; non-demented carriers of the Apolipoprotein E (ApoE) ε4 allele, a strong genetic risk factor for late-onset AD; cognitively normal subjects with a family history of AD; subjects with subjective memory complaints; and normal elderly followed longitudinally until they expressed the clinical symptoms and received post-mortem confirmation of AD. Finally, we will discuss the potential to combine different PET tracers and CSF markers of pathology to improve the early detection of AD.

Abstract

The development of prevention therapies for Alzheimer’s disease (AD) would greatly benefit from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical stage of the disease. Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of AD. In vivo brain 2-[ 18 F]fluoro-2-Deoxy-D-glucose-positron emission tomography (FDG-PET) imaging demonstrates consistent and progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before the onset of symptoms. This review will give an overview of FDG-PET results in individuals at risk for developing dementia, including: presymptomatic individuals carrying mutations responsible for early-onset familial AD; patients with Mild Cognitive Impairment (MCI), often a prodrome to late-onset sporadic AD; non-demented carriers of the Apolipoprotein E (ApoE) ε4 allele, a strong genetic risk factor for late-onset AD; cognitively normal subjects with a family history of AD; subjects with subjective memory complaints; and normal elderly followed longitudinally until they expressed the clinical symptoms and received post-mortem confirmation of AD. Finally, we will discuss the potential to combine different PET tracers and CSF markers of pathology to improve the early detection of AD.

참고문헌 (153)

  1. Kung HC, "Deaths: final data for 2005", Natl Vital Stat Rep, 56, pp.1~120 (2008)
  2. McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurol, 34, pp.939~944 (1984)
  3. Hebert LE, "Alzheimer disease in the US population: prevalence estimates using the 2000 census", Arch Neurol, 60, pp.1119~1122 (2003)
  4. Mirra SS, "The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease", Neurol, 41, pp.479~486 (1991)
  5. Price JL, "Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease", Ann Neurol, 45, pp.358~368 (1999)
  6. Braak H, "Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis", Acta Neuropathol, 92, pp.197~201 (1996)
  7. Delacourte A, "The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease", Neurol, 52, pp.1158~1165 (1999)
  8. Morris JC, "Cerebral amyloid deposition and diffuse plaques in “normal” aging: Evidence for presymptomatic and very mild Alzheiemer’s disease", Neurology, 46, pp.707~719 (1996)
  9. Braak H, "Neuropathological stageing of Alzheimer-related changes", Acta Neuropathol, 82, pp.239~259 (1991)
  10. Morrison JH, "Life and death of neurons in the aging brain", Science, 278, pp.412~419 (1997)
  11. Hyman BT, "Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation", Science, 225, pp.1168~1170 (1984)
  12. Etiene D, "Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer’s Disease", J Alzheimers Dis, 1, pp.119~134 (1998)
  13. Snowdon DA, "Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study", JAMA, 277, pp.813~817 (1997)
  14. Arriagada PV, "Distribution of Alzheimertype pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease", Neurology, 4, pp.1681~1688 (1992)
  15. Giannakopoulos P, "Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10- year autopsy population", Acta Neuropathol, 87, pp.456~468 (1994)
  16. Ulrich J, "Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer’s disease and senile dementia of Alzheimer type", Ann Neurol, 17, pp.273~277 (1985)
  17. Selkoe DJ, "Alzheimer’s disease: genotypes, phenotype, and treatments", Science, 275, pp.630~631 (1997)
  18. Lambert MP, "Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins", Proc Natl Acad Sci U S A, 통권 : 95, pp.6448~6453 (1998)
  19. Consensus report of the Working Group on, "“Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging", Neurobiol Aging, 19, pp.109~116 (1998)
  20. Nestor PJ, "Advances in the early detection of Alzheimer’s disease", Nat Med, 10, pp.S34~S41 (2004)
  21. de Leon MJ, "Abnormal cortisol response in Alzheimer’s disease linked to hippocampal atrophy", Lancet, 2, pp.391~392 (1988)
  22. de Leon MJ, "Early marker for Alzheimer’s disease: the atrophic hippocampus", Lancet, 2, pp.672~673 (1989)
  23. Jack CR Jr, "Rates of hippocampal atrophy correlate with change in clinical status in aging and AD", Neurology, 55, pp.484~489 (2000)
  24. Rusinek H, "Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging", Radiology, 229, pp.691~696 (2003)
  25. den Heijer T, "Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people", Arch Gen Psychiatry, 63, pp.57~62 (2006)
  26. O’Sullivan M, "Hippocampal volume is an independent predictor of cognitive performance in CADASIL", Neurobiol Aging, 30, pp.890~897 (2009)
  27. Sokoloff L, "Relation between physiological functions and energy metabolism in the central nervous system", J Neurochem, 29, pp.13~26 (1977)
  28. Magistretti PJ, "Energy on de mand", Science, 283, pp.496~497 (1999)
  29. Attwell D, "The neural basis of functional brain imaging signals", Trends Neurosci, 25, pp.621~625 (2002)
  30. Malonek D, "Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: implications for functional brain mapping", Science, 272, pp.551~554 (1996)
  31. Rocher AB, "Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons", Neuroimage, 20, pp.1894~1898 (2003)
  32. Magistretti PJ, "The contribution of astrocytes to the 18F- 2-deoxyglucose signal in PET activation studies", Mol Psychiatry, 1, pp.445~452 (1996)
  33. Pellerin L, "Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization", Proc Natl Acad Sci U S A, 통권 : 91, pp.10625~10629 (1994)
  34. Mosconi L, "Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD", Eur J Nucl Med Mol Imaging, 32, pp.486~510 (2005)
  35. fluorode-oxyglucose, "J Comput Assist Tomogr", 1983, 590~598
  36. Frackowiak RS, "A prospective study of regional cerebral blood flow and oxygen utilization in dementia using positron emission tomography and oxygen-15", J Cereb Blood Flow Metab, 1, pp.S453~S454 (1981)
  37. Minoshima S, "Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease", Ann Neurol, 42, pp.85~94 (1997)
  38. Ferris SH, "Positron emission tomography in the study of aging and senile dementia", Neurobiol Aging, 1, pp.127~131 (1980)
  39. Kim EJ, "Glucose metabolism in early onset versus late onset Alzheimer’s disease: an SPM analysis of 120 patients", Brain, 128, pp.1790~1801 (2005)
  40. Foster NL, "Cortical abnormalities in Alzheimer’s disease", Ann Neurol, 16, pp.649~654 (1984)
  41. Mazziotta JC, "Positron Emission Tomography studies of the brain. in: Positron Emission Tomography & Autoradiography: Principles & Applications for the Brain & Heart", pp.493~579 (1986), Raven Press
  42. Herholz K, "Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET", Neuroimage, 17, pp.302~316 (2002)
  43. Silverman DH, "Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome", JAMA, 286, pp.2120~2127 (2001)
  44. Szelies B, "Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia", Electroencephalogr Clin Neurophysiol, 91, pp.131~139 (1994)
  45. 45. Tanzi RE, "New frontiers in Alzheimer’s disease genetics", Neuron, 32, pp.181~184 (2001)
  46. Kennedy AM, "Chromosome 14 linked familial Alzheimer’s disease. A clinico-pathological study of a single pedigree", Brain, 118, pp.185~205 (1995)
  47. Kennedy AM, "Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheim r’s disease", Neurosci Lett, 186, pp.17~20 (1995)
  48. Mosconi L, "Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer’s disease", J Nucl Med, 47, pp.1778~1786 (2006)
  49. fluoro-2-deoxy-D-glucose, "positron-emission tomography (FDG", PET), 2001, pp.통권 : 98, 10966~10971
  50. Mosconi L, "Hippocampal hypometabolism predicts cognitive decline from normal aging", Neurobiol Aging, 29, pp.676~692 (2008)
  51. Petersen RC, "Practice parameter: early detection of dementia: mild cognitive impiarment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology", Neurology, 56, pp.1133~1142 (2001)
  52. Gauthier S, "Mild cognitive impairment", Lancet, 367, pp.1262~1270 (2006)
  53. Herholz K, "Impairment of neocortical metabolism predicts progression in Alzheimer’s disease", Dement Geriatr Cogn Disord, 10, pp.494~504 (1999)
  54. Arnaiz E, "Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment", Neuroreport, 12, pp.851~855 (2001)
  55. De Santi S, "Hippocampal formation glucose metabolism and volume losses in MCI and AD", Neurobiol Aging, 22, pp.529~539 (2001)
  56. Nestor PJ, "Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment", Ann Neurol, 54, pp.343~351 (2003)
  57. Chételat G, "Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease?", Neurology, 60, pp.1374~1377 (2003)
  58. Drzezga A, "Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study", Eur J Nucl Med Mol Imaging, 30, pp.1104~1113 (2003)
  59. Mosconi L, "Reduced hippocampal metabolism in MCI and AD: automated FDGPET image analysis", Neurology, 64, pp.1860~1867 (2005)
  60. Drzezga A, "Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET", J Nucl Med, 46, pp.1625~1632 (2005)
  61. Mosconi L, "Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET", Eur J Nucl Med Mol Imaging, 33, pp.210~221 (2006)
  62. Anchisi D, "Heterogeneity of brain glucose metaboism in mild cognitive impairment and clinical progression to Alzheimer disease", Arch Neurol, 62, pp.1728~1733 (2005)
  63. Haxby JV, "Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type", Arch Neurol, 47, pp.753~760 (1990)
  64. Reed BR, "Memory and regional cerebral blood flow in mildly symptomatic Alzheimer’s disease", Neurology, 39, pp.1537~1539 (1989)
  65. Berent S, "Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer’s disease", J Psychiatr Res, 33, pp.7~16 (1999)
  66. Mosconi L, "MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET", Neurology, 63, pp.2332~2340 (2004)
  67. Petersen RC, "Mild cognitive impairment: clinical characterization and outcome", Arch Neurol, 56, pp.303~308 (1999)
  68. Jagust W, "Brain imaging evidence of preclinical Alzheimer’s disease in normal aging", Ann Neurol, 59통권 : 6, pp.73~681 (2006)
  69. Skurk T, "Relationship between adipocyte size and adipokine expression and secretion", J Clin Endocrinol Metab, 92, pp.1023~1033 (2007)
  70. Corder EH, "Gene dose of apolipoprotein E type 4 Allele and the risk of Alzheimer’s disease in late onset families", Science, 261, pp.921~923 (1993)
  71. Farrer LA, "Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium", JAMA, 278, pp.1349~1356 (1997)
  72. Laws SM, "Expanding the association between the APOE gene and the risk of Alzheimer’s disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription", J Neurochem, 84, pp.1215~1236 (2003)
  73. Small GW, "Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease", JAMA, 273, pp.942~947 (1995)
  74. Reiman EM, "Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E", N Engl J Med, 334, pp.752~758 (1996)
  75. Small GW, "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease", Proc Natl Acad Sci U S A, 통권 : 97, pp.6037~6042 (2000)
  76. Reiman EM, "Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease", Proc Natl Acad Sci U S A, 통권 : 98, pp.3334~3339 (2001)
  77. Reiman EM, "Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia", Proc Natl Acad Sci U S A, 통권 : 101, pp.284~289 (2004)
  78. Reiman EM, "Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease", Ann Neurol, 44, pp.288~291 (1998)
  79. Mosconi L, "Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints", Biol Psychiatry, 63, pp.609~618 (2008)
  80. Geerlings MI, "Association between memory complaints and incident Alzheimer’s disease in elderly people with normal baseline cognition", Am J Psychiatry, 156, pp.531~537 (1999)
  81. Bobinski M, "MRI of entorhinal cortex in mild Alzheimer’s disease", Lancet, 353, pp.38~40 (1999)
  82. Cupples LA, "Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: the REVEAL study", Genet Med, 6, pp.192~196 (2004)
  83. Green RC, "Risk of dementia among white and African American relatives of patients with Alzheimer disease", JAMA, 287, pp.329~336 (2002)
  84. Silverman JM, "Variability of familial risk of Alzheimer disease across the late life span", Arch Gen Psychiatry, 62, pp.565~573 (2005)
  85. Mosconi L, "Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism", Proc Natl Acad Sci U S A, 통권 : 104, pp.19067~19072 (2007)
  86. Mosconi L, "Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease", Neurology, 72, pp.513~520 (2009)
  87. Lin MT, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases", Nature, 443, pp.787~795 (2006)
  88. Klunk WE, "Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B", Ann Neurol, 55, pp.306~319 (2004)
  89. Rowe CC, "Imaging beta-amyloid burden in aging and dementia", Neurology, 68, pp.1718~1725 (2007)
  90. PIB uptake in Alzheimer disease, "Neurology", 2006, 1575~1580
  91. Pike KE, "Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease", Brain, 130, pp.2837~2844 (2007)
  92. PIB in a nondemented population: potential antecedent marker of Alzheimer disease, "Neurology", 2006, 446~452
  93. Fagan AM, "Inverse relation between in vivo amyloid imaging load and c rebrospinal fluid Abeta42 in humans", Ann Neurol, 59, pp.512~519 (2006)
  94. Klunk WE, "Twoyear follow-up of amyloid deposition in patients with Alzheimer’s disease", Brain, 129, pp.2805~2807 (2006)
  95. Drzezga A, "Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease", Neuroimage, 39, pp.619~633 (2008)
  96. Mathis CA, "Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain", Curr Pharm Des, 10, pp.1469~1492 (2004)
  97. Lockhart A, "PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptiderelated cerebral amyloidosis", Brain, 130, pp.2607~2615 (2007)
  98. Agdeppa ED, "Binding characteristics of radiofluorinated 6-dialkylamino- 2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease", J Neurosci, 21, pp.RC189~ (2001)
  99. Small GW, "PET of brain amyloid and tau in mild cognitive impairment", N Engl J Med, 355, pp.2652~2663 (2006)
  100. de Leon MJ, "Seeing what Alzheimer saw", Nat Med, 13, pp.129~131 (2007)
  101. Powell MR, "Cognitive measures predict pathologic Alzheimer disease", Arch Neurol, 63, pp.865~868 (2006)
  102. Rowe CC, "Imaging of amyloid beta in Alzheimer’s disease with 18FBAY94- 9172, a novel PET tracer: proof of mechanism", Lancet Neurol, 7, pp.129~135 (2008)
  103. Mitchell A, "CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer’s disease?", Int J Geriat Psychiatry, 18, pp.407~411 (2003)
  104. Brys M, "CSF bio markers for mild cognitive impairment", J Aging Health, 2, pp.111~121 (2006)
  105. Blennow K, "CSF markers for incipient Alzheimer’s disease", Lancet Neurol, 2, pp.605~613 (2003)
  106. Blennow K, "Alzheimer’s disease", Lancet Neurology, 368, pp.387~403 (2006)
  107. Arai H, "CSF phosphorylated tau protein and mild cognitive impairment: a prospective study", Exp Neurol, 166, pp.201~203 (2000)
  108. Hansson O, "Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a followup study", Lancet Neurol, 5, pp.228~234 (2006)
  109. Brys M, "Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment", Neurobiol Aging, 30, pp.682~690 (2009)
  110. Büerger née Buch K, "Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer’s disease compared with controls", Neurosci Lett, 277, pp.21~24 (1999)
  111. Hulstaert F, "Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF", Neurology, 52, pp.1555~1562 (1999)
  112. Andreasen N, "Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice", Arch Neurol, 58, pp.373~379 (2001)
  113. Glodzik-Sobanska L, "The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer’s disease", Neurobiol Aging, 30, pp.672~681 (2009)
  114. Arai H, "Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology", Biochem Biophys Res Commun, 236, pp.262~264 (1997)
  115. Mollenhauer B, "Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimers disease", J Neural Transm, 112, pp.933~948 (2005)
  116. Hesse C, "Transient increase in total tau but not phosphotau in human cerebrospinal fluid after acute stroke", Neurosci Lett, 297, pp.187~190 (2001)
  117. Buerger K, "Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231", Arch Neurol, 59, pp.1267~1272 (2002)
  118. Buerger K, "Differentiation of geriatric major depression from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231", Am J Psychiatry, 160, pp.376~379 (2003)
  119. Buerger K, "Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease", Neurobiol Aging, 27, pp.10~15 (2006)
  120. Vanmechelen E, "Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization", Neurosci Lett, 285, pp.49~52 (2000)
  121. Sjögren M, "Both total and phosphorylated tau are increased in Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 70, pp.624~630 (2001)
  122. Ishiguro K, "Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease", Neurosci Lett, 270, pp.91~94 (1999)
  123. Parnetti L, "CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Phospho-Tau International Study Group", Neurol Sci, 22, pp.77~78 (2001)
  124. de Leon MJ, "Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment", Neurobiol Aging, 27, pp.394~401 (2006)
  125. de Leon MJ, "Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment", Neurosci Lett, 333, pp.183~186 (2002)
  126. Andreasen N, "CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease", Clin Neurol Neurosurg, 107, pp.165~173 (2005)
  127. Tapiola T, "Three-year follow-up of cerebrospinal fluid tau, B-amyloid 42 and 40 concentrations in Alzheimer’s disease", Neurosci Lett, 280, pp.119~122 (2000)
  128. Bading JR, "Brain clearance of Alzheimer’s amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy", J Drug Target, 10, pp.359~368 (2002)
  129. Silverberg GD, "Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study", Neurology, 59, pp.1139~1145 (2002)
  130. Silverberg GD, "The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type", Neurology, 57, pp.1763~1766 (2001)
  131. Peskind ER, "Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition", Arch Neurol, 63, pp.936~939 (2006)
  132. Fagan AM, "Cerebrospinal fluid tau", beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults, 2007, pp.64, 343~349
  133. Fukuyama R, "Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer’s disease patients", Eur Neurol, 43, pp.155~160 (2000)
  134. Shoji M, "The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently", Neurobiol Aging, 22, pp.209~215 (2001)
  135. Kanai M, "Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer’s disease: a study in Japan", Ann Neurol, 44, pp.17~26 (1998)
  136. Mehta PD, "Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease", Arch Neurol, 57, pp.100~105 (2000)
  137. Markesbery WR, "Oxidative stress hypothesis in Alzheimer’s disease", Free Radic Biol Med, 23, pp.134~147 (1997)
  138. Montine TJ, "The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer’s disease patients", Am J Pathol, 155, pp.863~868 (1999)
  139. Montine TJ, "Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer’s disease", Ann Neurol, 44, pp.410~413 (1998)
  140. Praticó D, "F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo", Atherosclerosis, 147, pp.1~10 (1999)
  141. Praticó D, "The isoprostanes in biology and medicine", Trends Endocrinol Metab, 12, pp.243~247 (2001)
  142. Nunomura A, "Oxidative damage is the earliest event in Alzheimer disease", J Neuropathol Exp Neurol, 60, pp.759~767 (2001)
  143. Praticó D, "Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis", J Neurosci, 21, pp.4183~34187 (2001)
  144. Markesbery WR, "Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment", Ann Neurol, 58, pp.730~735 (2005)
  145. Montine TJ, "Increased CSF F2-isoprostane concentration in probable AD", Neurology, 52, pp.562~565 (1999)
  146. Praticó D, "Increased 8,12-iso-iPF2alpha-VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity", Ann Neurol, 48, pp.809~812 (2000)
  147. Praticó D, "Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease", Arch Neurol, 59, pp.972~976 (2002)
  148. de Leon MJ, "Longitudinal CSF isoprostane and MRI atrophy in the progression to AD", J Neurol, 254, pp.1666~1675 (2007)
  149. Yao Y, "Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia", Neurology, 61, pp.475~478 (2003)
  150. Grossman M, "Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease", Ann Neurol, 57, pp.721~729 (2005)
  151. Montine TJ, "Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls", Arch Pathol Lab Med, 125, pp.510~512 (2001)
  152. Mosconi L, "Early detection of Alzheimer’s disease using neuroimaging", Exp Gerontol, 42, pp.129~138 (2007)
  153. Alexander GE, "Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies", Am J Psychiatry, 159, pp.738~745 (2002)

관련 논문AI추천

Biomarkers Predicting Alzheimer’s Disease in Cognitively Normal Aging심용수, John C. Morris대한신경과학회 · Journal of Clinical Neurology2011 · 제7권 제2호Systematic Review of Diagnostic Accuracy of Fluorodeoxyglucose Positron Emission Tomography for Alzheimer’s Disease김자영, 손수경, 손철호, 유영훈, 이동영, 이준영, 최지은한국보건의료기술평가학회 · 보건의료기술평가2017 · 제5권 제2호Diagnostic Tools for Alzheimer’s Disease: A Narrative Review Based on Our Own Research Experience문연실, Jang Jae Won, Kim Jae-Hun, Kim Min Young, Kwon Kyoung Ja, Moon Won-Jin, Park So-Hee, Ryu Hui Jin대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2023 · 제22권 제1호Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update김민경, 문소영, 박선아, 이선민, 장유정대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제4호알츠하이머 치매의 바이오마커-뇌영상 연구를 중심으로원왕연, 이창욱대한생물정신의학회 · 생물정신의학2011 · 제18권 제2호알츠하이머병 환자의 뇌 영상 검사의 최신 지견과임상 적용 방법강동우, 임현국대한신경정신의학회 · 신경정신의학2018 · 제57권 제1호

이 간행물의 다른 논문 (7건)

Aggressive Glucose Control for Acute Ischemic Stroke Patients by Insulin Infusion김나영, 권오현, 김병건, 이정주, 이지성, 구자성, 박종무, 장윤숙pp. 167-172Validity and Reliability of the Greek Version of the Multiple Sclerosis International Quality-of-Life QuestionnaireAris Triantafillou, Nikos Triantafyllou, Georgios Tsivgoulispp. 173-177Increased EEG Current-Source Density in the High Beta Frequency Band Induced by Levetiracetam Adjunctive Therapy in Refractory Partial Epilepsy박성파, 권오영pp. 178-185Clinical Diversity of SCN4A-Mutation-Associated Skeletal Muscle Sodium Channelopathy이상찬, 박영은, 최영철, 김대성, 박규현, 김향숙pp. 186-191A Novel PANK2 Mutation in a Patient with Atypical Pantothenate-Kinase-Associated Neurodegeneration Presenting with Adult-Onset Parkinsonism이필휴, 송숙근, 서주현pp. 192-194
원문 보기